Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...

Recent technological advances have set the stage for a renewed focus on human-based solutions called new approach ...

Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.

In 2019 I wrote about research suggesting anti-inflammatory medications might help some people with major depression. At the time, the idea that depression could have roots in the immune system felt ...

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

Patients with chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) have heightened innate immune responses to bacteria, viruses and fungi. While these responses are essential to fight infection ...

The FDA has granted priority review status for pegcetacoplan (Empaveli) to treat two rare kidney diseases that can lead to kidney failure. Up until now, there hadn’t been any drugs approved ...

In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains Miriam Freimer, MD, an author on 5 abstracts presented at the recent 15th ...